Measures of success

An artist's rendering of the UT Health San Antonio Multispecialty and Research Hospital, scheduled to open in 2024.
A rendering of the UT Health San Antonio Multispecialty and Research Hospital, scheduled to open in 2024. This 144-bed, best-in-class hospital will be the first of its kind with the most advanced treatments possible, and with more than 1,000 of the foremost experts in cancer, orthopaedics, ENT, urology, thoracic surgery and bariatrics, will offer comprehensive, coordinated care of the most complex cancer patients. The facility will include 12 operating rooms, two interventional suites, intensive care unit, labs, emergency department, imaging and bone marrow transplant.

An infographic snapshot of UT Health San Antonio’s Joe R. and Teresa Lozano Long School of Medicine

2022 Research Funding

$144.4 MILLION Total Organized Research Funding

$120.1 MILLION National Institutes of Health

$8.3 MILLION U.S. Department of Defense

$185.3 MILLION All Federal Funding

$190.3 MILLION Total Sponsored Programs Funding

 

Top 40 Departmental Blue Ridge Rankings

23 Pharmacology

25 Cellular & Integrative Physiology

25 Molecular Medicine

26 Cell Systems & Anatomy

29 Urology

30 Population Health Sciences

31 Neurology

36 Obstetrics & Gynecology

 

Centers and Institutes

The University of Texas Health Science Center at San Antonio is the only university in the United States with an NCI-designated Cancer Center, an NIA-funded Nathan Shock Center, an NIA-funded Claude Pepper Center, an NIA-designated Alzheimer’s Disease Research Center, and an NCATS-funded Clinical and Translational Science Institute.

Mays Cancer Center at UT Health San Antonio

South Texas’ only National Cancer Institute-Designated Cancer Center.

Sam and Ann Barshop Institute for Longevity and Aging Studies

The only aging center in the nation that holds two National Institute on Aging-funded care centers:

1. San Antonio Claude D. Pepper Older Americans Independence Center (1 of 14 in U.S.).

2. San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging (1 of 6 in U.S.).

Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases

The Biggs Institute is leading Texas’ only NIH-funded Alzheimer’s Disease Research Center. The institute provides a comprehensive network of clinical care with access to the most advanced treatment through clinical trials.

Institute for Integration of Medicine and Science

IIMS houses an NIH-funded Clinical and Translational Science Award and integrates laboratory and clinical research for UT Health San Antonio and its partners.

South Texas Research Organizational Network Guiding Studies on Trauma and Resilience

STRONG STAR is a multidisciplinary and multi-institutional research consortium funded by the Department of Defense and Veterans Administration to develop and evaluate the most effective early interventions possible for posttraumatic stress disorder.

 

Clinical Trials From Our Own Science

NCT04230499

Phase 2A Trial of Encapsulated Rapamycin (eRapa)to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

NCT04886622

A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, inPatients With Relapsed/Refractory Malignancies

NCT03776071

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added toTemozolomide During and Following RadiationTherapy in Newly Diagnosed Glioblastoma PatientsWho Possess the Novel Genomic Biomarker DGM1

NCT04608448

An Innovative Proof-of-concept Approach to Identify Age-modulating Drugs Capable of Reversing Inflammation and Re-setting the Epigenetic Clock (Topical-RAPA)

NCT04559230

A Phase 2, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma

NCT02342379

TH-302 in Combination with Bevacizumab for Glioblastoma

NCT03091660

S1602: Different Strains of BCG with or without Vaccine in High Grade Non-Muscle Invasive Bladder Cancer

NCT019063852

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

NCT Pending

Phase 2 Trial with a Safety Run-in Evaluation of GC4711, a MnSOD Mimetic, Combined with a CDK4/6 Inhibitor(Palb) and an Estrogen Therapy (ET) Agent (Fulv) in Women with ET-Resistance/Recurrent/Metastatic Disease

NCT Pending

A Subject-Blinded First-in-human Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of AST-004 as a Short Intravenous Infusion in Healthy Adult Subjects 


Share this post!


In the 2022 issue of Future

Future is the official magazine of the Joe R. & Teresa Lozano Long School of Medicine at The University of Texas Health Science Center at San Antonio. Read and share inspiring stories highlighting our medical alumni, faculty and students who are revolutionizing education, research, patient care and critical services in the communities they serve.

View the 2022 issue

Categories for this article :

Leave a Reply

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>